Note 12 - Segments

3 Months Ended

Mar. 31, 2024

Notes to Financial Statements

Segment Reporting Disclosure [Text Block]

NOTE 12 – SEGMENTS

The Company has determined its operating segments in accordance with ASC 280 – Segment Reporting. Factors used to determine the Company’s reportable segments include the availability of separate financial statements, the existence of locally based leadership across geographic regions, the economic factors affecting each segment, and the evaluation of operating results at the segment level. The Chief Operating Decision Maker (“CODM”) allocates the Company’s resources for each of the operating segments and evaluates their relative performance. Each operating segment listed below has separate financial statements and locally based leadership that are evaluated based on the results of their respective segments. It should be noted that the operating segments below have different products and services. The financial information is consolidated and evaluated regularly by the CODM in assessing performance and allocating resources.

The Company has three reportable segments, which have been delineated by location and business area:

● Pittsburgh segment: provides services that include the application of AI using its proprietary biobank of 150,000+ tumor samples. Pittsburgh also creates proprietary 3D culture models used in drug development.

● Birmingham segment: provides contract services and research focused on solubility improvements, stability studies, and protein production.

● Eagan segment: produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal.

All revenues are earned from external customers.

The tables below summarize the Company’s segment reporting as of March 31, 2024, and December 31, 2023, and for the three months ended March 31, 2024, and 2023.

	Three Months Ended March 31, 2024
	Pittsburgh			Birmingham			Eagan			Corporate			Total
Revenue	$	4,858		$	11,009		$	403,779		$	-		$	419,646
Depreciation and amortization		(32,097	)		(120,794	)		(7,823	)		(1,851	)		(162,565	)
Segment loss	$	(1,196,065	)	$	(465,162	)	$	(189,576	)	$	(2,368,040	)	$	(4,218,843	)

	March 31, 2024
	Pittsburgh		Birmingham		Eagan		Corporate		Total
Assets	$	3,135,259	$	840,518	$	1,612,484	$	5,012,926	$	10,601,187

	Three Months Ended March 31, 2023
	Pittsburgh			Birmingham			Eagan			Corporate			Total
Revenue	$	10,627		$	13,649		$	215,619		$	-		$	239,895
Depreciation and amortization		(111,822	)		(117,600	)		(6,778	)		(1,654	)		(237,854	)
Segment loss	$	(1,159,105	)	$	(482,696	)	$	(285,397	)	$	(1,494,604	)	$	(3,421,802	)

	December 31, 2023
	Pittsburgh		Birmingham		Eagan		Corporate		Total
Assets	$	3,263,270	$	981,914	$	1,390,031	$	8,782,034	$	14,417,249